The Medicines for Malaria Venture (MMV) is a product development partnership in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria by discovering, developing, and delivering new, effective, and affordable antimalarial drugs. In partnership with MMV, USAID helped advance Coartem Dispersible—the first child-friendly artemisinin-based combination therapy for malaria—from product development to widespread scale-up. This important pediatric drug has since been introduced in 50 countries worldwide. More recently, MMV supported the development of tafenoquine, a single-dose cure for relapsing malaria. Support from USAID has also contributed to the progression of three new classes of antimalarial drugs with the potential to be effective against drug-resistant strains of the parasite. These drugs may be promising alternatives to artemisinin-based formulations and are undergoing patient trials. Read about USAID's latest grant to MMV here.

Learn more at